Press Releases

Press Releases

Date Title and Summary Additional Formats
Dec 03, 2018 Catalyst Pharmaceuticals Announces Conference Call to Discuss Commercialization Plan for Firdapse® (amifampridine) for Lambert-Eaton Myasthenic Syndrome (LEMS)
U.S. launch scheduled for early in the first quarter of 2019   Catalyst is well-capitalized and sees no current need for capital infusion CORAL GABLES, Fla. , Dec. 03, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on
Nov 29, 2018 FDA Approves Firdapse® (amifampridine) for the Treatment of Lambert-Eaton Myasthenic Syndrome (LEMS)
- First evidenced-based medicine approved to treat LEMS - Catalyst Pathways™ designed to facilitate access to Firdapse® and provide dedicated patient support - Launch early in the first quarter of 2019 - Catalyst to hold conference call on December 13, 2018 at 8:30 AM ET to discuss launch details
Nov 27, 2018 Catalyst Pharmaceuticals Announces Firdapse® (amifampridine) New Drug Application Continues Under Review
FDA PDUFA goal date remains tomorrow, November 28, 2018 CORAL GABLES, Fla. , Nov. 27, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals Inc.  (Nasdaq:CPRX) today reports that no decision has yet been received from the Food and Drug Administration with respect to the company’s new drug application
Nov 07, 2018 Catalyst Pharmaceuticals Announces Third Quarter 2018 Financial Results and Provides Corporate Update
Company to Host Quarterly Conference Call at 8:30 am ET Tomorrow CORAL GABLES, Fla. , Nov. 07, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic
Oct 31, 2018 Catalyst Pharmaceuticals to Hold Third Quarter Financial Results and Corporate Update Conference Call and Webcast on Thursday, November 8th, 2018
CORAL GABLES, Fla. , Oct. 31, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today
Sep 20, 2018 Catalyst Pharmaceuticals to Participate in Two Upcoming Investor Conferences

Oppenheimer Fall Summit Focused on Specialty Pharma and Rare Disease on September 25-27 in New York City Cantor Fitzgerald Global Healthcare Conference on October 1-3 in New York City CORAL GABLES, Fla. , Sept. 20, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc.

Aug 29, 2018 Catalyst Pharmaceuticals to Present at Rodman & Renshaw’s 20th Annual Global Investment Conference

CORAL GABLES, Fla. , Aug. 29, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today

Aug 20, 2018 Catalyst Pharmaceuticals Appoints Dr. Stanley Iyadurai as Vice President of Clinical Development

CORAL GABLES, Fla. , Aug. 20, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today

Aug 07, 2018 Catalyst Pharmaceuticals Announces Second Quarter 2018 Financial Results and Provides Corporate Update

--Company to Host Quarterly Conference Call at 8:30 am ET Tomorrow CORAL GABLES, Fla. , Aug. 07, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating,

Aug 06, 2018 Catalyst Pharmaceuticals Expands Commercial Leadership Team

Augments Medical Affairs Team with 3 Additional Medical Science Liaisons CORAL GABLES, Fla. , Aug. 06, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare


Displaying 1 - 10 of 25